ESMO
ESMO21: Enhertu brings it’s A game to second-line breast cancer
Phil Taylor
AstraZeneca, Daiichi Sankyo, Enhertu, ESMO, HER2-positive breast cancer, Kadcyla, Roche
0 Comment
ESMO21: Roche’s giredestrant takes stage in battle of the oral SERDs
Phil Taylor
breast cancer, ESMO, Giredestrant, Oncology, Roche
0 Comment
ESMO21: First combo data with Amgen’s Lumakras hit the mark in CRC
Phil Taylor
Amgen, Boehringer Ingelheim, colorectal cancer, ESMO, KRAS, Lumakras, Oncology, Vectibix
0 Comment
Immunomedics wows ESMO with breast cancer data reveal
Richard Staines
breast cancer, ESMO, Gilead, Immunomedics, Roche, triple negative breast cancer
0 Comment
Oncology/ Views & Analysis/ Views and analysis
ESMO 2019 roundup
Richard Staines
AbbVie, Amgen, AstraZeneca, cancer, Clovis, ESMO, GSK, Merck & Co
0 Comment
ESMO 2019 – new data could unlock bigger market for PARP inhibitors
Phil Taylor
AbbVie, AstraZeneca, ESMO, GlaxoSmithKline, Lynparza, Oncology, ovarian cancer, Zejula
0 Comment
News/ News/ News/ Oncology/ R&D
ESMO 2019 – Amgen’s KRAS drug finds colorectal cancer a challenge
Phil Taylor
Amgen, colorectal cancer, ESMO, Oncology
0 Comment
As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer data
Phil Taylor
AstraZeneca, ESMO, GlaxoSmithKline, Lynparza, Oncology, ovarian cancer, PARP inhibitor, Zejula
0 Comment